Answers are grounded in this paper and cite their sources.
Demonstrates quantification of protein-bound uremic toxins in serum, suggesting insights into CKD-MBD.
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a severe complication of chronic kidney disease (CKD), linked to the systemic accumulation of protein-bound uremic toxins (PBUTs). Current methods for PBUT analysis are often constrained by limited analyte coverage and lack of integrated high-throughput quantification of multiple toxins. A high-throughput targeted Ultra-High-Performance Liquid Chromatography–Tandem Mass Spectrometry (UHPLC–MS/MS) method was developed and validated for the quantitative determination of PBUTs in human serum, including N δ -(carboxymethyl)lysine (CML) and pentosidine (PE). Reproducible sample preparation and reliable quantification were achieved using 96-well protein/phospholipid removal plates for sample preparation and optimizing chromatographic and mass spectrometric conditions. The method was validated, demonstrating acceptable linearity over the concentration range of 10–2000 ng/mL for all 15 analytes (R 2 > 0.99), with lower limits of quantification (LLOQ) of 10–20 ng/mL. The limits of detection (LOD) ranged from 5 to 10 ng/mL, and the precision expressed as relative standard deviation (RSD) was below 15%. Application to serum samples from 40 uremic patients and 20 healthy controls revealed significantly elevated levels of 10 PBUTs, with p-cresyl sulfate (PCS) concentrations approximately 400-fold higher in patients. Five PBUTs were undetectable in healthy individuals. This study provides a reliable and accurate method for PBUTs quantification, offering valuable insights into the critical role of PBUTs in the pathogenesis of CKD-MBD, and advancing PBUT-related metabolomic research. • Novel LC–MS/MS method simultaneously quantifies 15 protein-bound uremic toxins in serum. • 96-well plate processing enhances throughput, sensitivity, and reduces matrix effects. • P-cresyl sulfate levels were 400-fold higher in uremic patients versus controls. • Identified potential new biomarkers for CKD–mineral and bone disorder.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: